Key Points
- COO Kristen Oelschlager sold 12,218 Castle Biosciences shares at an average price of $33.69, generating $411,624; her remaining stake fell 12.56% to 85,033 shares.
- Castle Biosciences reported quarterly revenue of $99.86 million and an EPS loss of $0.07, beating analyst estimates, though the company remains unprofitable and is expected to post a full-year EPS loss.
- Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $42 price target; institutional investors own 92.6% of the company.
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) COO Kristen Oelschlager sold 12,218 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $33.69, for a total value of $411,624.42. Following the completion of the transaction, the chief operating officer directly owned 85,033 shares of the company's stock, valued at approximately $2,864,761.77. The trade was a 12.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Castle Biosciences Price Performance
Shares of NASDAQ CSTL opened at $34.08 on Thursday. Castle Biosciences, Inc. has a fifty-two week low of $17.72 and a fifty-two week high of $44.28. The firm's 50-day simple moving average is $26.73 and its 200 day simple moving average is $25.41. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. The stock has a market cap of $1.04 billion, a P/E ratio of -51.64 and a beta of 0.98.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.34. The firm had revenue of $99.86 million during the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. Equities analysts expect that Castle Biosciences, Inc. will post -1.29 EPS for the current year.
Hedge Funds Weigh In On Castle Biosciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CSTL. Federated Hermes Inc. purchased a new position in Castle Biosciences during the 4th quarter worth approximately $26,000. Kemnay Advisory Services Inc. purchased a new stake in shares of Castle Biosciences in the fourth quarter valued at $35,000. Global Retirement Partners LLC purchased a new stake in shares of Castle Biosciences in the second quarter valued at $26,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Castle Biosciences by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company's stock worth $55,000 after buying an additional 297 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Castle Biosciences by 140.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,750 shares of the company's stock worth $68,000 after buying an additional 1,022 shares during the period. Institutional investors and hedge funds own 92.60% of the company's stock.
Analysts Set New Price Targets
A number of research firms have weighed in on CSTL. Zacks Research downgraded Castle Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 26th. Roth Capital began coverage on Castle Biosciences in a research note on Wednesday, June 24th. They issued a "buy" rating and a $40.00 price objective on the stock. Weiss Ratings upgraded Castle Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, July 31st. BTIG Research boosted their price target on shares of Castle Biosciences from $40.00 to $44.00 and gave the stock a "buy" rating in a research report on Monday, August 3rd. Finally, Wall Street Zen upgraded Castle Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $42.00.
View Our Latest Stock Analysis on CSTL
Castle Biosciences Company Profile
(
Get Free Report)
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
